• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Study finds higher surgery risk with Bayer’s Essure

Study finds higher surgery risk with Bayer’s Essure

October 14, 2015 By MassDevice

Bayer's Essure(Reuters) — Women implanted with Bayer‘s (ETR:BAYN) Essure female sterilization device were more than 10 times more likely to require post-procedure surgery than those who underwent laparoscopic sterilization, according to a study published today in the British Medical Journal.

The findings could cast additional doubt on the safety of the Bayer device, which was approved in 2002 as an alternative to surgical sterilization and acquired by Bayer in 2013. It has faced recent scrutiny from U.S. health regulators following numerous patient complaints and calls for its withdrawal from the market.

By 1 year after the initial procedure, 2.4% of Essure patients had required follow-up surgery, compared with 0.2% of those who underwent a minimally-invasive tube-tying procedure called laparoscopic sterilization, the researchers found. That translates to about 21 additional surgeries per 1,000 patients receiving Essure, they said.

“Small risk in large numbers of patients translates into large numbers,” said study leader Dr. Art Sedrakyan, professor of healthcare policy and research at Weill Cornell Medicine in New York. “In some instances, these re-operations are quite major surgeries,” including hysterectomies, Sedrakyan added.

The study analyzed coding data on medical records of some 52,000 women from outpatient ambulatory surgical centers in New York state between 2005 and 2013.

If the New York data were to be extrapolated to Essure use throughout the U.S., it works out to about 10,000 patients getting this type of additional surgery, Sedrakyan said.

Both methods of contraception were equally effective, with about a 1% risk of unintended pregnancies.

Bayer, in a statement, defended the safety and efficacy of its device and cited limitations of the study, including that it was “based on a single database of 1 U.S. state” and unclear if it included patients who had Essure implantation in doctors’ offices.

Bayer estimates there are about 750,000 women using Essure worldwide, about 70% of them in the U.S.

Essure consists of 2 small nickel-titanium coils inserted into the fallopian tubes. Scar tissue forming around the device acts to block the tubes and prevent pregnancy.

Personal injury lawsuits filed against Bayer have claimed the implant led to allergic reactions to nickel, severe pelvic pain, and surgeries to stabilize or remove the device after it shifted. More than 5,000 adverse events have been reported to the FDA, though it is not always clear what role Essure played in any event.

An FDA advisory panel last month recommended that the agency limit Essure’s use until more is known about its safety.

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Gynecological, Regulatory/Compliance, Women's Health Tagged With: Bayer

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy